deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT01101906

A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC

A Randomized, Placebo-controlled, Double-blinded Phase 2 Study of Second-line Treatment With OSI-906 in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure of First-line Treatment With Sorafenib

Sponsor: Astellas Pharma Inc

Conditions Advanced Hepatocellular Carcinoma (HCC)
Interventions OSI-906 Placebo
Updated 14 times since 2017 Last updated: Nov 18, 2024 Started: Jan 10, 2011 Primary completion: Nov 4, 2011 Completion: Dec 28, 2011
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Company decided not to pursue the development of this drug in this patient population at this time

Other terminated trials from Astellas Pharma Inc

More terminations from Astellas Pharma Inc

Other Advanced Hepatocellular Carcinoma (HCC) trials with similar outcome

Browse all Advanced Hepatocellular Carcinoma (HCC) trials

This PHASE2 trial investigates Advanced Hepatocellular Carcinoma (HCC) and is currently terminated or withdrawn. Astellas Pharma Inc leads this study, which shows 14 recorded versions since 2011 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshot~Aug 2017 – ~May 2018 · 9 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Nov 2020 · 25 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Apr 2022 · 4 months · monthly snapshot~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Sep 2025 · 9 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Dec 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Sep 2024 — Dec 2024 [monthly]

    Terminated PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  5. Apr 2022 — Jul 2024 [monthly]

    Terminated PHASE2

▶ Show 9 earlier versions

  1. Dec 2021 — Apr 2022 [monthly]

    Terminated PHASE2

  2. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

  3. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE2

  4. Oct 2018 — Nov 2020 [monthly]

    Terminated PHASE2

  5. Jun 2018 — Oct 2018 [monthly]

    Terminated PHASE2

  6. May 2018 — Jun 2018 [monthly]

    Terminated PHASE2

  7. Aug 2017 — May 2018 [monthly]

    Terminated PHASE2

  8. Feb 2017 — Aug 2017 [monthly]

    Terminated PHASE2

  9. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Astellas Pharma Inc
Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Bondy, France , Brussells, Belgium , Busan, South Korea , Changhua, Taiwan , Créteil, France , Daegu, South Korea , Essen, Germany , Ghent, Belgium , Goyang-si, South Korea and 24 more locations